Get notified when RXRX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRisk Profile Improvements
- Departure Of Cmo (new) — The Chief Medical Officer is departing after approximately three years in the role, though the structured transition with advisory period suggests a planned change rather than abrupt exit.
Recursion appoints oncology veteran Vicki Goodman as Chief Medical Officer
Filed March 25, 2026 · Period ending March 25, 2026 · ~1 min read
Key Changes
-
high
Vicki Goodman, M.D., joins as CMO effective April 6, 2026, bringing 20+ years oncology drug development experience including senior roles at Exelixis (CMO), Merck (KEYTRUDA late-stage lead), and Bristol Myers Squibb (OPDIVO/YERVOY development lead).
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR → -
medium
David Mauro, M.D., Ph.D., transitions out after approximately three years as CMO, continuing in advisory capacity through May 29, 2026 to support the handoff.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR → -
medium
Company states pipeline advancement and clinical/regulatory milestones remain consistent with previously communicated expectations, providing context for the planned leadership transition timing.
Exhibit 99.1 verify on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (QRED 10-Q) is open in full — no account needed.
Partner
Trade RXRX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 22, 2026 12:35 AM